Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
AlloVir Inc. (ALVR) Insider Trading Activity
Healthcare • Biotechnology • 8 employees
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Total Value
-$46,595.38
Total Shares
-53,649
Average Trade Value
-$1,503.08
Most Active Insider
Brainard Diana
Total Activity: $22,764
Largest Single Transaction
$9,176
by Brainard Diana on Nov 5, 2024
30-Day Activity
3 Transactions
Volume: 505 shares
Value: $5,088
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
See Remarks
|
Feb 21, 2025 | 303 | $3,053 | 49,129 (-0.6%) | Sale | |
|
Chief Accounting Officer
|
Feb 21, 2025 | 96 | $967 | 2,832 (-3.4%) | Sale | |
|
General Counsel
|
Feb 21, 2025 | 106 | $1,068 | 6,517 (-1.6%) | Sale | |
|
See Remarks
|
Jan 23, 2025 | 116 | $1,097 | 49,445 (-0.2%) | Sale | |
|
See Remarks
|
Jan 23, 2025 | 13 | $129 | 49,432 (-0.0%) | Sale | |
|
Chief Accounting Officer
|
Jan 23, 2025 | 4 | $40 | 2,928 (-0.1%) | Sale | |
|
Chief Accounting Officer
|
Jan 23, 2025 | 32 | $303 | 2,932 (-1.1%) | Sale | |
|
General Counsel
|
Jan 23, 2025 | 5 | $50 | 6,623 (-0.1%) | Sale | |
|
General Counsel
|
Jan 23, 2025 | 47 | $444 | 6,628 (-0.7%) | Sale | |
|
General Counsel
|
Jan 10, 2025 | 409 | $180 | 153,541 (-0.3%) | Sale | |
|
Chief Accounting Officer
|
Jan 10, 2025 | 332 | $146 | 68,174 (-0.5%) | Sale | |
|
See Remarks
|
Jan 10, 2025 | 979 | $431 | 1,139,915 (-0.1%) | Sale | |
|
Chief Accounting Officer
|
Nov 19, 2024 | 554 | $304 | 68,506 (-0.8%) | Sale | |
|
General Counsel
|
Nov 19, 2024 | 432 | $237 | 211,499 (-0.2%) | Sale | |
|
See Remarks
|
Nov 19, 2024 | 3,186 | $1,748 | 1,140,894 (-0.3%) | Sale | |
|
Chief Executive Officer
|
Nov 19, 2024 | 8,706 | $4,775 | 723,363 (-1.2%) | Sale | |
|
Chief Executive Officer
|
Nov 5, 2024 | 10,609 | $9,176 | 732,069 (-1.4%) | Sale | |
|
Chief Accounting Officer
|
Nov 5, 2024 | 1,655 | $1,431 | 69,060 (-2.4%) | Sale | |
|
See Remarks
|
Nov 5, 2024 | 5,136 | $4,442 | 1,144,080 (-0.4%) | Sale | |
|
General Counsel
|
Nov 5, 2024 | 2,272 | $1,965 | 211,931 (-1.1%) | Sale | |
|
See Remarks
|
Oct 22, 2024 | 1,882 | $1,445 | 1,149,216 (-0.2%) | Sale | |
|
General Counsel
|
Oct 22, 2024 | 766 | $588 | 214,203 (-0.4%) | Sale | |
|
Chief Accounting Officer
|
Oct 22, 2024 | 486 | $373 | 70,715 (-0.7%) | Sale | |
|
Chief Accounting Officer
|
Oct 21, 2024 | 479 | $373 | 71,201 (-0.7%) | Sale | |
|
See Remarks
|
Oct 21, 2024 | 1,546 | $1,204 | 1,151,098 (-0.1%) | Sale | |
|
General Counsel
|
Oct 21, 2024 | 635 | $495 | 214,969 (-0.3%) | Sale | |
|
Chief Executive Officer
|
Oct 21, 2024 | 9,752 | $7,597 | 742,678 (-1.3%) | Sale | |
|
General Counsel
|
Oct 3, 2024 | 377 | $307 | 215,604 (-0.2%) | Sale | |
|
Chief Accounting Officer
|
Oct 3, 2024 | 301 | $245 | 71,680 (-0.4%) | Sale | |
|
Chief Executive Officer
|
Oct 3, 2024 | 1,493 | $1,217 | 752,430 (-0.2%) | Sale | |
|
See Remarks
|
Oct 3, 2024 | 940 | $766 | 1,152,644 (-0.1%) | Sale |